<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355821</url>
  </required_header>
  <id_info>
    <org_study_id>MOXOC001</org_study_id>
    <nct_id>NCT02355821</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women</brief_title>
  <acronym>COMPASS</acronym>
  <official_title>Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1&#xD;
      C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several experimental studies have demonstrated that moxonidine may lower the activity of Na+-&#xD;
      independent Cl-/bicarbonate exchanger (anion exchanger, AE) which plays an essential role in&#xD;
      viability of osteoclasts that are crucial for bone resorption. The suppression of AE proteins&#xD;
      activity has been proven to inhibit osteoclast activity and reduce bone resorption whereas&#xD;
      the moxonidine molecule is known to reduce the AE protein activity. Therefore, the results of&#xD;
      experimental studies have shown the ability of moxonidine to inhibit bone resorption through&#xD;
      its effect on the osteoclast activity.&#xD;
&#xD;
      Published data contain information on positive effects of beta-blockers on the bone tissue&#xD;
      condition. There are data which clearly demonstrate a positive effect of beta-blockers on&#xD;
      bone mass.&#xD;
&#xD;
      The proposed trial is a comprehensive study of moxonidine effects on processes of cellular&#xD;
      and vascular aging as well as bone metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collagen Type 1 C-telopeptide</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomerase Activity</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity (PWV)</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intima-media Thickness (IMT)</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>THe Number (Percentage) of the Treatment Responders</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure &lt;140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
    <description>Number of Participants with Adverse Events (AE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Osteopenia</condition>
  <condition>Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
    <arm_group_label>Moxonidine</arm_group_label>
    <other_name>Physiotens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
    <arm_group_label>Bisoprolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female with age 45 years and older.&#xD;
&#xD;
          2. Postmenopausal (absence of menstrual periods for a minimum of 12 months) at the moment&#xD;
             of Informed Consent sign.&#xD;
&#xD;
          3. Arterial hypertension grade I / II per ESH/ESC 2013 guidelines (diastolic pressure ≥&#xD;
             90 and &lt;110 mm Hg, systolic pressure ≥140 and &lt;180 mm Hg).&#xD;
&#xD;
          4. Not achieving BP targets &lt;140/90 mmHg either during antihypertensive therapy or naive.&#xD;
&#xD;
          5. Absence of moxonidine or bisoprolol treatment at least 6 months before the study&#xD;
&#xD;
          6. Osteopenia of lumbar spine and/or proximal part of the femur (osteoporosis T-score&#xD;
             from -1 to -2.5 standard deviations [SD]) by X-Ray densitometry.&#xD;
&#xD;
          7. Signed Informed Consent for participation in the study&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to moxonidine, bisoprolol or any other ingredient of the respective&#xD;
             formulations&#xD;
&#xD;
          2. Any Contraindications for moxonidine, bisoprolol&#xD;
&#xD;
          3. Osteoporosis (Т-score below - 2.5 SD).&#xD;
&#xD;
          4. Primary or secondary hyperparathyroidism.&#xD;
&#xD;
          5. Paget's disease of bones.&#xD;
&#xD;
          6. History of low traumatic bone fractures.&#xD;
&#xD;
          7. Malabsorption syndrome.&#xD;
&#xD;
          8. History of gastro-intestinal surgery.&#xD;
&#xD;
          9. Severe disturbance of peripheral circulation.&#xD;
&#xD;
         10. Raynaud's disease.&#xD;
&#xD;
         11. Symptomatic (secondary) hypertension (caused by any primary internal diseases)&#xD;
&#xD;
         12. Morbid obesity (BMI over 40 kg/m2).&#xD;
&#xD;
         13. Symptoms of estrogen deficiency such as hot flushes, nights sweat, vaginal dryness&#xD;
&#xD;
         14. Administration of any hormone-replacement therapy (HRT) or intake of isoflavones&#xD;
&#xD;
         15. Secondary hypogonadism.&#xD;
&#xD;
         16. Sistolic BP ≥180 mm Hg and/or Diastolic BP ≥110 mm Hg.&#xD;
&#xD;
         17. Clinical presentations of cardiovascular disease: coronary heart disease (CHD),&#xD;
             history of stroke, transient ischemic attack (TIA), Charcot's syndrome.&#xD;
&#xD;
         18. Severe heart failure.&#xD;
&#xD;
         19. Hemodynamically significant congenital heart disease.&#xD;
&#xD;
         20. Heart rhythm disorders which require permanent use of any antiarrhythmic medications&#xD;
             (including β-adrenoblockers and calcium antagonists).&#xD;
&#xD;
         21. Diabetes mellitus of any genesis.&#xD;
&#xD;
         22. Severe liver failure.&#xD;
&#xD;
         23. Severe kidney failure including patients on dialysis&#xD;
&#xD;
         24. Thyroid diseases accompanied by functional disorders (thyrotoxicosis or uncompensated&#xD;
             hypothyroidism).&#xD;
&#xD;
         25. Alcohol and drug abuse.&#xD;
&#xD;
         26. Patients with oncological diseases diagnosed within 5 years before IC execution.&#xD;
&#xD;
         27. Inability of the patient to comprehend the essence of the program and to provide&#xD;
             his/her consent for participation in the program.&#xD;
&#xD;
         28. Patients with any condition, which in the opinion of the Investigator makes the&#xD;
             patient unsuitable for inclusion based on clinical judgment.&#xD;
&#xD;
         29. Corticosteroid therapy&#xD;
&#xD;
         30. Participation in any other clinical study during the whole course of this&#xD;
             investigation including participation in a study within 30 days prior to providing the&#xD;
             informed consent for this trial&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga N Tkacheva, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>tkacheva@rambler.ru</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Research Center for Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://elibrary.ru/item.asp?id=22652971</url>
    <description>The review of a new data is provided related to novel aspects of moxonidine use in the patients with arterial hypertension. The main attention is paid to the problem of vascular ageing, telomere biology and calcium-phosphorus homeostasis</description>
  </link>
  <link>
    <url>http://elibrary.ru/item.asp?id=21347559</url>
    <description>The aim was to assess the effects of moxonidine in terms of target blood pressure achievement; to identify potential additional benefits of moxonidine and its effects on bone metabolism and bone mineral density in postmenopausal women</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <results_first_submitted>June 17, 2020</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cellular aging</keyword>
  <keyword>vascular aging</keyword>
  <keyword>bone metabolism</keyword>
  <keyword>collagen type 1 C-telopeptide</keyword>
  <keyword>nuclear factor kappa-B ligand (RANKL)</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>telomerase activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02355821/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Moxonidine</title>
          <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
        <group group_id="P2">
          <title>Bisoprolol</title>
          <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moxonidine</title>
          <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
        <group group_id="B2">
          <title>Bisoprolol</title>
          <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.96" spread="9.1"/>
                    <measurement group_id="B2" value="60.5" spread="9.1"/>
                    <measurement group_id="B3" value="62" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone resorption marker (collagen type 1 C-telopeptide)</title>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="B2" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                    <measurement group_id="B3" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Collagen Type 1 C-telopeptide</title>
        <description>Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Collagen Type 1 C-telopeptide</title>
          <description>Changes in Median (Inter-Quartile Range) of the bone resorption marker (collagen type 1 C-telopeptide) at the end of the study from the baseline are evaluated in comparison between the groups</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin</title>
        <description>Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups.</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin</title>
          <description>Changes in Median (Inter-Quartile Range) values of the bone synthesis marker (osteocalcin) at the end of the study (V4) from the baseline (V1) and to compare the values between the groups.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="12.4" upper_limit="21.9"/>
                    <measurement group_id="O2" value="19.4" lower_limit="12.4" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="15.4" upper_limit="23.5"/>
                    <measurement group_id="O2" value="18.7" lower_limit="12.8" upper_limit="22.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).</title>
        <description>Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL).</title>
          <description>Changes in Median (Inter-Quartile Range) values of the receptor activator of nuclear factor kappa-B ligand (RANKL) at final visit versus baseline level in comparison between the groups</description>
          <units>pmol/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" lower_limit="0.06" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.133" lower_limit="0.06" upper_limit="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="0.05" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.111" lower_limit="0.07" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry</title>
        <description>Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups</description>
        <time_frame>12 months</time_frame>
        <population>Total hip BMD</population>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) Using Control Dual-energy X-ray Absorptiometry</title>
          <description>Changes in Median (Inter-Quartile Range) values of Bone mineral density (BMD) at final visit versus baseline level using control dual-energy X-ray absorptiometry and in comparison between the groups</description>
          <population>Total hip BMD</population>
          <units>g/cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.7" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.55" lower_limit="-1.3" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-0.9" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-1.9" upper_limit="-0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Telomerase Activity</title>
        <description>Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median.</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Telomerase Activity</title>
          <description>Changes in Median (Inter-Quartile Range) telomerase activity at final visit versus baseline level in comparison between the groups Telomerase activity is measured in arbitrary units. Currently, there are no established reference values for telomerase activity in the world. Its activity is considered high or low in relation to the median.</description>
          <units>arbitrary units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.16" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.16" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="0.74" upper_limit="1.59"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.46" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Wave Velocity (PWV)</title>
        <description>Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Wave Velocity (PWV)</title>
          <description>Changes in mean pulse wave velocity (PWV) at final visit versus baseline level and in comparison between the groups</description>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.35" spread="2.56"/>
                    <measurement group_id="O2" value="10.36" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.05" spread="2.29"/>
                    <measurement group_id="O2" value="11.26" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intima-media Thickness (IMT)</title>
        <description>Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups.</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Intima-media Thickness (IMT)</title>
          <description>Changes in mean intima-media thickness (IMT) at final visit in comparison between the groups.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.17"/>
                    <measurement group_id="O2" value="0.98" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.14"/>
                    <measurement group_id="O2" value="0.88" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>THe Number (Percentage) of the Treatment Responders</title>
        <description>Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure &lt;140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups.</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>THe Number (Percentage) of the Treatment Responders</title>
          <description>Proportion of the treatment responders (defined as the proportion (%) of patients who achieved target blood pressure &lt;140/90 mmHg) after 8 and 48 weeks of the investigated treatment (V2, V3 and V4) and to compare the values between the groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE)</title>
        <description>Number of Participants with Adverse Events (AE)</description>
        <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxonidine</title>
            <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
          <group group_id="O2">
            <title>Bisoprolol</title>
            <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE)</title>
          <description>Number of Participants with Adverse Events (AE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline (Visit 1) and 12 months (Visit 4)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Moxonidine</title>
          <description>0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID&#xD;
Moxonidine: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
        <group group_id="E2">
          <title>Bisoprolol</title>
          <description>5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID&#xD;
Bisoprolol: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ekaterina Dudinskaya, head of age-related metabolic and endocrine disorders laboratory</name_or_title>
      <organization>RGNKC</organization>
      <phone>+79031914690</phone>
      <email>katharina.gin@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

